Little pink pill

‘Female Viagra’ pill only has 200 takers so far

Addyi (Sprout Pharmaceuticals)

The pill being touted as women’s answer to “Viagra” — promising to boost libido if taken every day, not just at the time of sex — has failed to take off with female patients since its release, according to Bloomberg News. Since becoming available in October, only 227 prescriptions have been written for Addyi, the brand name pharmaceutical for the drug flibanserin, which faced controversy ahead of its approval due to its modest ability to actually boost desire and a host of side effects. The pill aims to treat hypoactive sexual desire disorder, but only boosts the libido in about 10 percent more patients than a placebo, and women cannot drink alcohol while taking it in order to avoid fainting, according to the report.

Comparatively, more than half a million men received Viagra prescriptions during its first month of sales in 1998. According to Bloomberg, the $26-per-pill price tag (the same as Viagra, but Viagra can be taken only when needed for a sexual boost instead of every day) makes the pill prohibitively expensive to some. On top of that, only about 1 percent of doctors are certified to recommend it to their patients. Still, the drug’s developers have already made out well. Sprout Pharmaceuticals, which developed the drug with private investors, was bought by the drug giant Valeant for $1 billion after the pill was approved for sale.

Read the full story at Bloomberg.

Related:

CEO of company behind Addyi says female sexuality is about biology, not just psychology

“Female Viagra” caused dissent at FDA, memo shows

FDA panel backs approval of women’s libido drug flibanserin … with a catch

Leave a Reply

Your email address will not be published. Required fields are marked *